Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus

The binding profile of [3H]8-hydroxy-2-(di-N-propylamino)-tetralin ([3H]8-OH-DPAT) to serotonin1A (5-HT1A) sites in rat hippocampal, frontocortical and striatal membranes has been compared. In these regions, [3H]8-OH-DPAT labels both a high and a low-affinity binding site; the affinity values for each of the two sites are comparable in the different brain regions, but have different maximal capacity. By modifying the experimental conditions in a series of hippocampal membrane preparations, reciprocal changes in the proportion of the two sites were observed suggesting that they represent, at least in this region, different conformations or affinity states of a single receptor protein. In contrast to the lower affinity state, it appears that the high-affinity state is stabilized by coupling with a G-protein. Evidence supporting this statement is provided by addition of the guanine nucleotide Gpp(NH)p, breakage of labile disulfide bonds using N-ethylmaleimide and increasing membrane rigidity with ascorbate-induced lipid peroxidation, conditions which all reduced the density of receptors in the high-affinity state. Moreover, the high-affinity state appears to be stabilized at the expense of the lower affinity state in the presence of Mn2+. On the other hand, a complete shift to the low-affinity binding state was observed after a 24 h in vivo treatment with inhibitors of monoamine oxidase A (phenelzine or clorgyline) but not of monoamine oxidase B (deprenyl). This disappearance of the high-affinity state with a concomitant increase in the binding capacity of the low-affinity state was reproduced by inhibiting monoamine oxidase A in vitro, as well as by reducing preincubation washout periods. Also, competitors of the [3H]8-OH-DPAT binding site, such as serotonin and unlabelled 8-OH-DPAT, display two affinity states while others like (+/-)-propranolol, tryptamine and spiperone recognize a single affinity component. These results suggest that the 5-HT1A binding site may exhibit at least two different affinity states depending upon its microenvironment and the intrinsic activity of the ligand used.

[1]  S. Maayani,et al.  Inhibition of forskolin-stimulated adenylate cyclase activity by 5-HT receptor agonists. , 1985, European journal of pharmacology.

[2]  R. Heikkila.  Ascorbate-induced lipid peroxidation and the binding of [3H]dihydroalprenolol. , 1983, European journal of pharmacology.

[3]  M. Wood,et al.  [3H]8‐OH‐DPAT labels the 5‐Hydroxytryptamine uptake recognition site and the 5‐HT1A binding site in the rat striatum , 1988, The Journal of pharmacy and pharmacology.

[4]  M. Caron,et al.  Effector coupling mechanisms of the cloned 5-HT1A receptor. , 1989, The Journal of biological chemistry.

[5]  B. Bacon,et al.  Guanyl nucleotide interactions with dopaminergic binding sites labeled by [3H]spiroperidol in human caudate and putamen: guanyl nucleotides enhance ascorbate-induced lipid peroxidation and cause an apparent loss of high affinity binding sites. , 1988, Molecular pharmacology.

[6]  J. Glowinski,et al.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT , 1983, Nature.

[7]  M. Hekman,et al.  Receptor Modification and Receptor Disposition in Membranes , 1987 .

[8]  J. Bockaert,et al.  Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. , 1988, Molecular pharmacology.

[9]  Y. Kitamura,et al.  Uncoupling of Rat Cerebral Cortical α2‐Adrenoceptors from GTP‐Binding Proteins by N‐Ethylmaleimide , 1987, Journal of neurochemistry.

[10]  C. Finch,et al.  Effects of radioligand oxidation and ascorbate‐induced lipid peroxidation on serotonin‐1 receptor assay: Use of ascorbate and ethylenediamine tetraacetic acid buffers to prevent (3H)‐5‐HT binding artifacts , 1988, Journal of neuroscience research.

[11]  F. Artaud,et al.  Biochemical evidence for the 5-HT agonist properties of PAT (8-hydroxy-2-(di-n-propylamino)tetralin) in the rat brain. , 1984, European journal of pharmacology.

[12]  R. Ciaranello,et al.  Differential inactivation and G protein reconstitution of subtypes of [3H]5-hydroxytryptamine binding sites in brain. , 1988, Molecular pharmacology.

[13]  M. Hamon,et al.  [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)Tetralin Binding to Pre‐ and Postsynaptic 5‐Hydroxytryptamine Sites in Various Regions of the Rat Brain , 1985, Journal of neurochemistry.

[14]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[15]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[16]  H. V. Van Tol,et al.  Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. , 1990, The Journal of biological chemistry.

[17]  B. Vallee,et al.  [36] Reactions with N-ethylmaleimide and p-mercuribenzoate. , 1972, Methods in enzymology.

[18]  P. Hochstein,et al.  Dual Effects of Ascorbate on Serotonin and Spiperone Binding in Rat Cortical Membranes , 1983, Journal of neurochemistry.

[19]  R. Lefkowitz,et al.  Multiple reactive sulfhydryl groups modulate the function of adenylate cyclase coupled beta-adrenergic receptors. , 1979, Molecular pharmacology.

[20]  A. Herbet,et al.  Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. , 1978, Molecular pharmacology.

[21]  J. Bockaert,et al.  Serotonin 5-HT1 receptors mediate inhibition of cyclic AMP production in neurons. , 1986, European journal of pharmacology.

[22]  S. Peroutka.  5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization , 1988, Trends in Neurosciences.

[23]  Y. Vladimirov,et al.  The increase of phospholipid bilayer rigidity after lipid peroxidation , 1977, FEBS letters.

[24]  W. Lovenberg,et al.  Chronic MAO A and MAO B inhibition decreases the 5-HT1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase. , 1988, European journal of pharmacology.

[25]  H. Schoemaker,et al.  [3H]8-OH-DPAT labels the serotonin transporter in the rat striatum. , 1986, European journal of pharmacology.

[26]  S H Snyder,et al.  Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. , 1979, Molecular pharmacology.

[27]  R. Floyd,et al.  Hydroxyl free radical formation from hydrogen peroxide by ferrous iron-nucleotide complexes. , 1983, Biochemistry.

[28]  M. Hamon,et al.  Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins. , 1990, Biochemical pharmacology.

[29]  D. Middlemiss,et al.  8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. , 1983, European journal of pharmacology.

[30]  M. Hamon,et al.  The GTP‐Insensitive Component of High‐Affinity [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)tetralin Binding in the Rat Hippocampus Corresponds to an Oxidized State of the 5‐Hydroxytryptamine1A Receptor , 1991, Journal of neurochemistry.

[31]  J. Ieni,et al.  The 5-HT1A receptor probe [3H]8-OH-DPAT labels the 5-HT transporter in human platelets. , 1988, Life sciences.

[32]  G A McPherson,et al.  A practical computer-based approach to the analysis of radioligand binding experiments. , 1983, Computer programs in biomedicine.

[33]  S. Peroutka,et al.  Modulation of 5‐Hydroxytryptamine1A Receptor Density by Nonhydrolyzable GTP Analogues , 1990, Journal of neurochemistry.

[34]  S. Peroutka,et al.  Pharmacological Differentiation and Characterization of 5‐HT1A, 5‐HT1B, and 5‐HT1C Binding Sites in Rat Frontal Cortex , 1986, Journal of neurochemistry.

[35]  D. Middlemiss,et al.  Stereoselective blockade at the 5-HT autoreceptor and inhibition of radioligand binding to central 5-HT recognition sites by the optical isomers of methiothepin , 1986, Neuropharmacology.